Showing results (361-370 of 382) with videos related to

Sort By:
Pageof 39
Journal for Immunotherapy of Cancer|April 3, 2020
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceHarriet M Kluger, Hussein A Tawbi, Maria L Ascierto, et al.
Cell Reports. Medicine|February 27, 2026
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trialCasey R Ager, Aleksandar Obradovic, Patrick McCann, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Oncotarget|July 10, 2018
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancerKarim Boudadi, Daniel L Suzman, Valsamo Anagnostou, et al.
Future Oncology (London, England)|April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
European Urology|September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate CancerChristina Guo, Ines Figueiredo, Bora Gurel, et al.
Nature Biotechnology|January 15, 2020
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigensGeoffrey M Lynn, Christine Sedlik, Faezzah Baharom, et al.
Cell|February 1, 2024
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasionGiuseppe Leuzzi, Alessandro Vasciaveo, Angelo Taglialatela, et al.
Immunity|August 7, 2024
The cytokine Meteorin-like inhibits anti-tumor CD8+ T cell responses by disrupting mitochondrial functionChristopher M Jackson, Ayush Pant, Wikum Dinalankara, et al.
Pageof 39